Sinopharm announces board committee structure and leadership

Sinopharm Group Co. Ltd. announced its board of directors and their committee appointments as of December 19, 2025. The board comprises non-executive directors, executive directors, and independent non-executive directors. Jin Bin serves as the chairman of the board and holds the position of chairman in both the nomination committee and the strategy and investment committee, while also being a member of the legal and compliance and environmental, social and governance committee. Lian Wanyong is the president and an executive director, serving as a member of the strategy and investment committee and the legal and compliance and environmental, social and governance committee.

The company operates with five distinct board committees: audit, remuneration, nomination, strategy and investment, and legal and compliance and environmental, social and governance. Independent non-executive directors play significant roles across these committees. Li Peiyu is a member of the audit committee and strategy and investment committee, and chairman of the remuneration committee. Wu Tak Lung chairs the audit committee and is a member of the remuneration and nomination committees. Yu Weifeng is chairman of the legal and compliance and environmental, social and governance committee and a member of the remuneration and nomination committees. Shi Shenghao is a member of the audit, nomination, and strategy and investment committees, while Chen Weiru is a member of both the nomination and strategy and investment committees.

The announcement reaffirms Sinopharm Group Co. Ltd. as a joint stock limited company incorporated in the People's Republic of China.